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Abstract
The AMP-activated protein kinase (AMPK) is an important regulator of endothelial metabolic and functional homeostasis.
Here, we examined the regulation of AMPK by nitrated oleic acid (OA-NO2) and investigated the implications in endothelial
function. Treatment of bovine aortic endothelial cells (BAECs) with OA-NO2 induced a significant increase in both AMPK-
Thr172 phosphorylation and AMPK activity as well as upregulation of heme oxygenase (HO)-1 and hypoxia-inducible factor
(HIF)-1a. Pharmacologic inhibition or genetic ablation of HO-1 or HIF-1a abolished OA-NO2-induced AMPK phosphorylation.
OA-NO2 induced a dramatic increase in extracellular signal-regulated kinase (ERK)1/2 phosphorylation that was abrogated
by the HO-1 inhibitor, zinc deuteroporphyrin IX 2,4-bis-ethylene glycol (ZnBG). Inhibition of ERK1/2 using UO126 or
PD98059 reduced but did not abolish OA-NO2-induced HIF-1a upregulation, suggesting that OA-NO2/HO-1-initiated HIF-1a
induction is partially dependent on ERK1/2 activity. In addition, OA-NO2 enhanced endothelial intracellular Ca
2+, an effect
that was inhibited by the HIF-1a inhibitor, YC-1, and by HIF-1a siRNA. These results implicate the involvement of HIF-1a.
Experiments using the Ca
2+/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor STO-609, the selective CaMKII
inhibitor KN-93, and an isoform-specific siRNA demonstrated that OA-NO2-induced AMPK phosphorylation was dependent
on CaMKKb. Together, these results demonstrate that OA-NO2 activates AMPK in endothelial cells via an HO-1–dependent
mechanism that increases HIF-1a protein expression and Ca
2+/CaMKKb activation.
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Introduction
Accumulating evidence indicates that reactive nitrogen species
(RNS), which are inflammatory oxidants, mediate diverse
physiologic and pathologic processes in cardiovascular, pulmo-
nary, and neurodegenerative diseases [1]. RNS, such as perox-
ynitrite (ONOO
2), nitrogen-dioxide radical, and nitronium ion,
which are formed from nitric oxide (NO), are important factors in
complications of obesity and diabetes [2]. RNS react with
unsaturated fatty acids to form relatively stable nitrated products
(nitroalkene derivatives), including the abundant and clinically
important nitrated oleic and linoleic acids [3]. Although this
process occurs via various mechanisms, the common denominator
is a proclivity for homolytic addition of nitrogen dioxide (NNO2)t o
the double bond, yielding an array of regio- and stereoisomers [4].
Nitrated unsaturated fatty acids (NO2-UFAs) represent a conver-
gence of lipid and NO signaling and have emerged as a novel class
of endogenously produced vascular signaling molecules [5]. The
beneficial effects of NO2-UFAs include cGMP-dependent vessel
relaxation, inhibition of inflammatory cell function, adaptive and
anti-inflammatory cell responses, induction of heme oxygenase-1
(HO-1) expression, inhibition of nuclear factor (NF)-kB, and
activation of peroxisome proliferator activated receptor (PPAR)
and Keap1/Nrf2 [6].
Plasma free and esterified nitrated oleic acid (OA-NO2)
concentrations have been reported to be 619652 and
3026369 nM, respectively, and these levels are approximately
50% greater than the level of nitrated linoleic acid (LNO2). The
combined blood levels of the free and esterified fatty acid
derivatives exceeds 1 mM [4]. The plasma levels of NO2-UFA
derivatives in hyperlipidemic patients are elevated relative to levels
in normolipidemic subjects [7]. In addition, an increase in
oxidative stress in hypercholesterolemia [8] may contribute to
the formation of nitrated species in the vascular wall [9]. Thus,
nitrated lipids in the plasma can be used as an indicator of the
chain-breaking antioxidant role of NO in lipid oxidation [10]
and/or provide a footprint for the presence of oxidants/nitrating
agents in the vascular system. We postulate that the presence of
these nitrated products in vivo promote cardiovascular homeostasis
and compensate for impaired vascular endothelial function in the
context of dyslipidemia, obesity, and diabetes. The molecular
target(s) and mechanisms underlying the vascular-protective and
anti-inflammatory effects of NO2-UFAs remain poorly defined.
The serine/threonine kinase, AMP-activated protein kinase
(AMPK), is a member of the Snf1/AMPK protein kinase family
that is found in all eukaryotes [11]. This kinase is thought to act as
a cellular energy sensor by stimulating ATP-producing catabolic
pathways and inhibiting ATP-consuming anabolic pathways [12].
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regulatory b- and c-subunits. Activation of AMPK requires the
phosphorylation of Thr172 in the activation loop of the a-subunit
by an upstream AMPK kinase (AMPKK) [13]. Interestingly, the
first AMPKK to be identified was LKB1, a tumor suppressor that
is mutated in humans with Peutz-Jegher syndrome [14]. Patients
with this syndrome have an increased risk of developing
carcinomas of the colon, stomach, and pancreas. Recently,
calcium (Ca
2+) calmodulin-dependent kinase kinase (CaMKK)
[15] was identified as an upstream AMPKK. CaMKK is activated
by a rise in intracellular Ca
2+ concentrations ([Ca
2+]i), and this
kinase phosphorylates and activates AMPK in an AMP-indepen-
dent manner [15]. Therefore, in addition to responding to an
increase in the AMP-to-ATP ratio, AMPK may also be activated
by a rise in [Ca
2+]i in response to nutrients, drugs, or physiological
stimuli. While the AMPK pathway is traditionally thought to be a
regulator of metabolism, recent studies have demonstrated that
AMPK may also act to maintain endothelial function [16]. AMPK
exerts pleiotropic effects that are believed to be beneficial for
endothelial function. These effects, which are ultimately anti-
atherogenic, include induction of the endothelial nitric oxide
synthase (eNOS)/NO pathway and result in an increase in NO
bioavailability, suppression of endothelial ROS production
following exposure to deleterious stimuli, such as hyperglycemia
or high free fatty acids (FFAs), and modulation of vascular tone
(see review [16]). AMPK also possesses anti-apoptotic and anti-
inflammatory activities [17].
Since many of the metabolic changes and endothelial-protective
effects attributable to NO2-UFAs are similar to those observed in
response to AMPK activation, we hypothesized that AMPK
activation is an important mediator of NO2-UFA activity. As such,
AMPK activation may explain the pleiotropic beneficial effects of
NO2-UFAs on the cardiovascular system in obesity and diabetes.
Whether NO2-UFAs activate AMPK and, if so, by what
mechanism(s) has yet to be determined. In the present study, we
examined the effects of NO2-UFAs on the AMPK upstream
kinases, specifically LKB1 and CaMKKb. We also investigated
whether NO2-UFAs modulate the eNOS/NO pathway, which is
known to be an indicator of endothelial function and an important
property of AMPK in cardiovasculature. We report that treatment
with NO2-UFAs induces CaMKKb-dependent AMPK activation
through an HO-1/HIF-1a/Ca
2+ pathway in vitro and show that
NO2-UFAs promote p-eNOS and NO production via activation of
the AMPK pathway in endothelial cells.
Results
OA-NO2 induces HO-1 protein and AMPK
phosphorylation/activation in bovine aortic endothelial
cells (BAECs)
To investigate activation of AMPK by OA-NO2 in endothelial
cells, we treated confluent BAECs with different concentrations of
OA-NO2 for 2–16 h. AMPK activation was indirectly assessed by
western blot analysis of AMPK Thr172 phosphorylation, which is
essential for AMPK activity [18]. As shown in Figure 1A and 1B,
incubation of BAECs with OA-NO2 (0.5–2.5 mM for 16 h, or
2.5 mM for 2–16 h) resulted in a dose- and time-dependent
increase in AMPKa phosphorylation at Thr172. AMPK Thr172
phosphorylation in BAECs gradually increased beginning 6 h after
incubation with 2.5 mM OA-NO2 and reached peak levels after
16 h. This increased AMPK phosphorylation was associated with
elevated AMPK activity, as measured by the SAMS peptide assay
(Figure 1C). OA-NO2 treatment did not alter total AMPK levels,
suggesting that OA-NO2-induced phosphorylation of AMPK was
not due to altered expression of these proteins. Since OA-NO2
activated AMPK in both BAECs and human umbilical vein
endothelial cells (HUVECs) at similar potencies, we performed the
majority of our experiments with BAECs.
The changes in AMPK phosphorylation were mirrored by
changes in HO-1 protein expression, as evaluated by western blot
analysis. Exposure of BAECs to a range of OA-NO2 concentra-
tions resulted in an upregulation of HO-1 that was initially
observed at 4 h with peak induction at 16 h. HO-1 induction and
AMPK activation were specifically due to the nitroalkene moiety
of OA-NO2, because oleic acid (OA) did not induce HO-1 protein
expression or AMPK phosphorylation (Figure 1D). At a
concentration of 2.5 mM, OA-NO2 potently activated AMPK
and induced HO-1 expression without causing cellular toxicity.
On the basis of these results, we chose to stimulate BAECs with
2.5 mM OA-NO2 for 16 h in subsequent experiments.
To determine whether OA-NO2-induced HO-1 expression was
mediated by AMPK, we used an adenovirus encoding a dominant-
negative mutant form of AMPKa (Ad-DN-AMPK) to suppress
AMPK activity. AICAR (5-aminoimidazole-4-carboxamide-1-b-
D-ribofuranoside) and metformin, two well characterized AMPK
activators, were used as positive controls for AMPK phosphory-
lation. OA-NO2 significantly elevated AMPK phosphorylation
(Figure 1E). As expected, Ad-DN-AMPK effectively suppressed
AMPK phosphorylation but failed to abolish HO-1 induction by
OA-NO2, suggesting that AMPK does not act upstream of HO-1
production in this system.
Activation of AMPK by OA-NO2 does not require LKB1
Two recent studies [14,19] showed that LKB1 acts as an
upstream AMPK kinase. To evaluate the role of LKB1 in OA-
NO2-induced AMPK activation, we investigated whether OA-
NO2 altered LKB1 Ser 428 phosphorylation, which is essential for
LKB1 activity and LKB1-dependent AMPK activation. As shown
in Figure 2A, OA-NO2 did not alter the levels of LKB1 Ser428
phosphorylation.
We next determined whether OA-NO2 activated AMPK in
Hela-S3 cells, an LKB1-deficient cell line. Similar to the results
obtained in BAECs, OA-NO2 (2.5 mM) induced AMPK phos-
phorylation on Thr172 in Hela-S3 cells (,3-fold, p,0.05;
Figure 2B). In parallel with AMPK phosphorylation, OA-NO2
dramatically increased phosphorylation of the known AMPK
substrate, acetyl-CoA carboxylase (ACC), at Ser79 (,2.4-fold,
p,0.05), providing an additional indication that AMPK was
activated in the absence of LKB1. To further explore the role of
LKB1, we investigated the effect of siRNA-mediated LKB1
downregulation on AMPK activation induced by OA-NO2.A s
shown in Figure 2C, OA-NO2-induced AMPK phosphorylation
was not significantly altered in cells pre-treated with LKB1 siRNA.
The suppression of LKB1 protein expression by LKB1 siRNA
(,60%) was confirmed by western analysis. Taken together, these
results strongly suggest that OA-NO2-induced phosphorylation of
AMPK Thr172 is independent of its upstream kinase, LKB1.
Induction of HIF-1a by OA-NO2 is dependent on HO-1
Hypoxia-inducible factor (HIF)-1 is a dimeric protein complex
that plays an integral role in the body’s response to hypoxia [20].
Like AMPK, HIF-1 is one of the primary genes involved in the
homeostatic process that leads to increased vascularization in
hypoxic areas, such as those within localized ischemia and in
tumors [20]. HIF-1 and AMPK represent two main cellular
pathways involved in coping with hypoxic stress and protecting
cells against energy depletion and tissue reperfusion injury in times
of metabolic crisis [21]. In addition, both HIF-1 and HO-1 are
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induced both HO-1 expression and AMPK activation, we
determined whether OA-NO2 also influenced HIF-1 expression.
As predicted, OA-NO2 induced an increase in HIF-1a in
HUVECs with a time course similar to OA-NO2-induced HO-1
expression and AMPK phosphorylation (Figure 3A). To explore
the potential involvement of HO-1 in OA-NO2-induced HIF-1a
expression, we pre-treated cells with the selective HO inhibitor
zinc deuteroporphyrin IX 2,4-bis-ethylene glycol (ZnBG) and
HO-1-specific siRNA. As shown in Figure 3A and B, ZnBG and
HO-1 siRNA treatment abrogated the induction of HIF-1a
protein expression and AMPK phosphorylation by OA-NO2,
suggesting that OA-NO2 acts through the induction of HO-1 to
increase HIF-1a expression and subsequently activate AMPK.
The efficacy of the HO-1 siRNA in the downregulation of HO-1
expression was confirmed by western analysis (Figure 3B).
ERK1/2 is partially responsible for OA-NO2/HO-1-
mediated HIF-1a induction
Clearly, the HIF pathway plays an important role in the
regulation of metabolism under hypoxic conditions; however, a
variety of HIF-1 stimuli function independently of oxygen
concentration. These stimuli are primarily mediated by proteins
that regulate HIF-1 translation. This pathway contrasts with
hypoxic stimuli, which act upon pre-existing a-subunits [20]. HIF-
1a activation by non-hypoxic stimuli has been linked primarily to
the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway and the
mitogen-activated protein kinase (MAPK) pathway [22]. Both
kinase pathways are known to be intimately associated with the
regulation of HIF-1a protein translation, stabilization, and
transcriptional activity [23]. Our data indicate that OA-NO2 did
not activate PI3-K/Akt (data not shown). To determine whether
OA-NO2-mediated HIF-1a induction is dependent on the MAPK
pathway, we examined p38 MAPK and extracellular signal-
regulated kinase 1/2 (ERK1/2) phosphorylation following stim-
ulation with OA-NO2. Treatment with OA-NO2 induced a dose-
dependent increase in the phosphorylation of ERK1/2 and p38
MAPK (Figure 4A). ZnBG inhibited OA-NO2-induced activation
of ERK1/2, suggesting a role for HO-1 in this activation
(Figure 4B).
We next determined whether ERK1/2 was a potential
upstream mediator of OA-NO2-induced HIF-1a upregulation
using the ERK1/2 inhibitor, UO126 (10 mM), and the MAPK/
ERK kinase (MEK)-specific inhibitor PD98059 (50 mM). Pre-
treatment of BAECs with UO126 or PD98059 decreased HIF-1a
levels by approximately 50% relative to cells treated with OA-NO2
Figure 1. Induction of HO-1 protein and AMPK activation by OA-NO2.A ) BAECs were incubated with OA-NO2 at the indicated
concentrations or with BSA (vehicle) for 16 h, and western blot analysis was performed as described in Materials and Methods to detect HO-1 protein
expression and AMPK phosphorylation at Thr172. The blot is representative of those obtained from three separate experiments. Corresponding
densitometric analyses of phosphorylated AMPK and ACC are shown. *p,0.05 vs. control. B) BAECs were incubated with 2.5 mM OA-NO2 for the
indicated times, and western blotting was performed as above. The blot is representative of three blots obtained from three separate experiments.
*p,0.05 vs. corresponding control. C) Confluent BAECs were exposed to vehicle or OA-NO2 (2.5 mM) for 16 h. AMPKa was immunoprecipitated from
cell lysates (1 mg) with a specific antibody. AMPK activity was assayed by
32P-ATP incorporation into the SAMS peptide. *p,0.05 vs. control. D) BAECs
were incubated with the indicated concentrations of OA for 16 h. Western blotting was performed as described in Materials and Methods. E) BAECs
were infected with Ad-DN-AMPK (MOI=50) or Ad-GFP (control). Infected and non-infected cells were treated with 2.5 mM OA-NO2 for 16 h. AICAR
and metformin were used as positive controls. The blot is representative of three blots obtained from three separate experiments.
doi:10.1371/journal.pone.0031056.g001
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induction is due, at least in part, to MEK/ERK1/2 activity.
UO126 and PD98059 did not affect basal HIF-1a expression. In
addition to increasing HIF-1a expression, ERK1/2 has previously
been reported to phosphorylate HIF-1a in vitro, and this post-
translational modification can increase HIF-1a activity, presum-
ably by impeding proteasome/von-Hippel-Lindau (VHL) recog-
nition [20]. Although very little is known about the phosphory-
lation of HIF-1a, this phosphorylation event may be important for
optimal activity of the HIF-1 pathway.
HIF-1a induction by OA-NO2 contributes to intracellular
Ca
2+ accumulation and AMPK activation
To examine the involvement of the HIF-1a pathway in OA-
NO2-mediated AMPK activation, we employed the widely used
HIF-1a inhibitor, 3-(59-hydroxymethyl-29-furyl)-1-benzylindazole
(YC-1) and HIF-1a siRNA. Pre-treatment of BAECs with YC-1 or
HIF-1a siRNA significantly inhibited the OA-NO2-induced
increase in AMPK Thr172 phosphorylation levels relative to
OA-NO2 treatment alone (Figure 5A and B). Since OA-NO2-
induced AMPK activation is LKB1-independent, we postulated
that the Ca
2+/CaMKK pathway plays a role in the activation of
AMPK by OA-NO2/HIF-1a. In addition, because HIF-1a has
been reported to regulate Ca
2+ homeostasis in pulmonary arterial
smooth muscle cells via upregulation of store-operated Ca
2+
channels and enhanced Ca
2+ influx [24], we examined a possible
role for HIF-1a in this process. To determine whether OA-NO2
affected endothelial cell [Ca
2+]i, we measured intracellular
fluorescence in Fluo-4–loaded BAECs. We found that OA-NO2
treatment produced an approximately 1.4- to 2.2-fold increase in
[Ca
2+]i at 6 and 16 h after treatment, respectively (Figure 5C). To
confirm a role for HIF-1a in this OA-NO2-mediated [Ca
2+]i
increase, we used pharmaceutical- and genetic-inhibition strategies
to downregulate HIF-1a. Pre-treatment of BAECs with YC-1 or
transfection of these cells with HIF-1a siRNA partially suppressed
the OA-NO2-induced increases in [Ca
2+]i (Figure 5D), indicating
that this process is at least partially dependent on HIF-1a.W e
Figure 2. Activation of AMPK by OA-NO2 does not require LKB1. A) Phosphorylation of LKB1 Ser428 was not affected by OA-NO2 in BAECs.
Confluent BAECs were exposed to 2.5 mM OA-NO2 for 16 h, and phosphorylated LKB1-Ser428 was detected by a phospho-specific antibody in
western blots. The blot is a representative of three blots obtained from three independent experiments. Lower panels: summary data (n=3). B) LKB1
is not required for AMPK activation by OA-NO2. Confluent LKB1-deficient Hela-S3 cells were exposed to 2.5 mM OA-NO2 for 16 h, and then AMPK and
ACC phosphorylation were assayed as described in Materials and Methods. The blot is representative of three blots obtained from three independent
experiments. Lower panels: summary data (*p,0.05 vs. control; n=3). C) LKB1 siRNA did not abolish OA-NO2-stimulated AMPK activation in HUVECs.
HUVECs were incubated with LKB1-specific siRNA or control siRNA for 48 h and then treated with OA-NO2 or vehicle for 16 h. After treatment, cell
lysates were analyzed for LKB1 protein levels and AMPK phosphorylation at Thr172. Lower panels: summary data (*p,0.05 vs. control; n=3).
doi:10.1371/journal.pone.0031056.g002
Figure 3. OA-NO2-induced HIF-1a is dependent on HO-1.
A) HUVECs were treated with 1 mM ZnBG for 30 min followed by
incubation with OA-NO2 for the indicated times. AMPK protein and
phosphorylation levels and HIF-1a protein expression were assayed as
described in Materials and Methods. The blot is representative of three
blots obtained from three independent experiments. B) HUVECs were
incubated with HO-1-specific siRNA or control siRNA for 48 h and then
treated with OA-NO2 or vehicle for 16 h. After treatment, cell lysates
were analyzed for HIF-1a and HO-1 protein levels and AMPK
phosphorylation at Thr172. Lower panels: summary data (*p,0.05 vs.
control;
#p,0.05 vs. OA-NO2 group; n=3).
doi:10.1371/journal.pone.0031056.g003
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2+ signal is involved in OA-NO2-
induced AMPK activation using BAPTA-AM, a cell-permeable
Ca
2+ chelator that is widely used as an intracellular Ca
2+
‘‘sponge’’. Our results indicate that chelation of intracellular
Ca
2+ by BAPTA-AM (25 mM, 30 min) significantly inhibited
OA-NO2-stimulated AMPK phosphorylation (,60%, p,0.05;
Figure 5E). Together, these data show that intracellular Ca
2+ is
necessary for OA-NO2-induced AMPK activation.
CaMKKb mediates OA-NO2-induced AMPK activation
Both the tumor suppressor LKB1 [14] and CaMKK [15] are
important AMPK kinases as each activates AMPK by directly
phosphorylating the AMPK a subunit on Thr172. As shown
above (Figure 2A–C), LKB1 is unlikely involved in the activation
of AMPK by OA-NO2. Because treatment with OA-NO2
elevated [Ca
2+]i and OA-NO2-stimulated AMPK activation
was Ca
2+ sensitive, we speculate that the AMPK kinase,
CaMKKb, which is activated by Ca
2+/calmodulin binding,
may be involved. To test this hypothesis, we used the relatively
selective CaMKKa and CaMKKb inhibitor, STO-609 (1 mM)
[25] and the competitive CaM inhibitor, KN-93 (3 mM). Either
STO-609 or KN-93 was sufficient to prevent activation of
AMPK by OA-NO2 (Figure 6A), suggesting the involvement of
CaMKK in this activation. A specific role for CaMKKb was
indicated by the results of siRNA experiments, which showed
that downregulation of CaMKKb caused a significant reduction
in OA-NO2-stimulated AMPK phosphorylation (Figure 6B).
Downregulation of CaMKKb protein was verified by western
blot analysis. These results suggest that CaMKKb is the major
AMPK kinase under these conditions. To further validate this
notion, we determined whether treatment with OA-NO2
enhanced the association between CaMKK and AMPK as this
interaction is a prerequisite for AMPK phosphorylation/
activation. Indeed, following OA-NO2 treatment, an enhanced
CaMKK and AMPK association was detected by immunopre-
cipitation with either AMPK or CaMKK antibodies (Figure 6C).
Moreover, pre-treatment with YC-1 dramatically inhibited the
OA-NO2-induced increased CaMKK-AMPK association, fur-
ther substantiating the indispensable role of HIF-1a in OA-NO2-
induced AMPK activation.
OA-NO2-induced eNOS phosphorylation is dependent on
AMPK
We previously demonstrated that AMPK phosphorylates and
activates eNOS in cultured endothelial cells [26]. Similarly,
Zhang et al. demonstrated that infection of endothelial cells with
a recombinant adenovirus expressing constitutively active
AMPK resulted in eNOS activation and increased NO
production [27]. Here, we used phosphorylation of Ser1177 in
eNOS, which is a reported substrate of AMPK, as an indicator
of AMPK activity in this system. As shown in Figure 7A,
incubation of BAECs with OA-NO2 increased eNOS Ser1177
phosphorylation in a dose-dependent manner that was very
similar to that for AMPK phosphorylation. The time course of
OA-NO2–induced eNOS phosphorylation was also similar to
that for AMPK phosphorylation (Figure 7B). To confirm that
OA-NO2-stimulated eNOS phosphorylation involved AMPK,
we infected BAECs with adenovirus encoding a dominant-
negative form of AMPK (Ad-DN-AMPK). As expected,
phosphorylation of both AMPK and eNOS was increased after
treatment of control BAECs (Ad-GFP-infected or non-infected
BAECs) with 2.5 mMO A - N O 2 for 16 h (Figure 7C). In contrast,
overexpression of Ad-DN-AMPK completely abolished OA-
NO2-induced eNOS phosphorylation. Consistent with a role for
AMPK in phosphorylating eNOS, treatment with STO-609 or
KN-93 to inhibit the AMPK kinase CaMKK or downregulation
of CaMKKb using siRNA prevented OA-NO2-induced eNOS
phosphorylation (Figure 6A and B).
Both Akt and AMPK are capable of phosphorylating eNOS at
Ser1179 [28]. Thus, we determined whether Akt also contributes
to OA-NO2-induced eNOS phosphorylation. OA-NO2 did not
increase basal Akt phosphorylation of Ser473 (data not shown),
suggesting that OA-NO2-stimulated eNOS phosphorylation does
not require Akt but depends on activation of AMPK.
Figure 4. OA-NO2-induced HIF-1a is partially dependent on ERK1/2. A) BAECs were incubated with the indicated concentrations of OA-NO2
for 16 h. Protein expression and phosphorylation of p38 MAPK and ERK1/2 were assayed as described in Materials and Methods. The blot is
representative of three blots obtained from three independent experiments. B) BAECs were treated with ZnBG (1 mM) for 30 min followed by
incubation with OA-NO2 for 16 h. ERK1/2 phosphorylation levels were monitored by immunoblot analysis, and band density was normalized to total
ERK1/2 levels (lower panel). The blot is representative of three blots obtained from three independent experiments. *p,0.05 vs. control;
#p,0.05 vs.
OA-NO2 group. C) BAECs were treated with OA-NO2 alone or with the ERK1/2 signaling inhibitors, UO126 (10 mM) or PD98059 (50 mM), 1 h before the
addition of OA-NO2. HIF-1a protein levels were monitored by immunoblot analysis, and band density was normalized to b-actin levels (lower panel).
The blot is representative of three blots obtained from three independent experiments. *p,0.05 vs. control;
#p,0.05 vs. OA-NO2 group.
doi:10.1371/journal.pone.0031056.g004
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phorylation was associated with increased NO release. Treatment
with OA-NO2 significantly increased NO release, an effect that
was inhibited by Ad-DN-AMPK transfection (Figure 7D). Impor-
tantly, Ad-DN-AMPK transfection reduced AMPK activity in
OA-NO2-treated cells to below control levels (Figure 7E). These
results indicate that OA-NO2 increases NO release via AMPK
activation.
Discussion
OA-UFAs are unique signaling mediators that are present in a
variety of cell types, including endothelial cells [29]. Considerable
evidence points to a role for circulating OA-UFAs in vascular-
protective effects [9], although the mechanisms by which OA-NO2
are incompletely understood. In this study, we report that OA-
NO2 activates AMPK in endothelial cells via a Ca
2+-dependent
pathway, and we implicate CaMKKb as the responsible upstream
kinase. Our results show that HIF-1a is an inducer of the
intracellular Ca
2+ mobilization that leads to AMPK activation. On
the basis of the results of experiments with an HO-inhibitor and
HO-1 siRNA, we also implicate HO-1 in OA-NO2-induced
upregulation of endothelial HIF-1a.
HO is a rate-limiting enzyme in heme degradation and
functions to convert heme to biliverdin, carbon monoxide (CO)
and iron. Human HO occurs in two main isoforms, the inducible
HO-1 form and the constitutive HO-2 form. Previous studies
demonstrated that HO-1 exerts anti-inflammatory effects [30],
including prolongation of cardiac xenograft graft survival [31] and
inhibition of leukocyte transendothelial migration during comple-
ment-dependent inflammation [32] and in response to low-density
lipoprotein (LDL) oxidation [33]. More importantly, once
induced, HO-1 also confers vascular cytoprotection [30]. The
importance of this result is demonstrated by the severe and
persistent endothelial damage observed in the case of human HO-
1 deficiency [34] and in gene-targeted mice deficient in HO-1
[35]. Furthermore, induction of HO-1 may directly regulate
endothelial cell activation, preventing adhesion molecule expres-
sion and chronic graft rejection [36]. In vitro, HO-1 protects
endothelial cells from hydrogen peroxide–mediated cell death [37]
and from tumor necrosis factor a (TNFa) cytotoxicity [38]. In
addition, HO-1 has been suggested to play a role in angiogenesis.
Figure 5. HIF-1a mediates OA-NO2-induced intracellular Ca
2+ accumulation and AMPK activation. A) BAECs were treated with YC-1
(30 mM) for 30 min followed by incubation with OA-NO2 for the indicated times. AMPK phosphorylation and protein levels were assayed as described
in Materials and Methods. The blot is representative of three blots obtained from three independent experiments. B) BAECs were incubated with HIF-
1a-specific siRNA or control siRNA for 48 h and then treated with OA-NO2 or vehicle for 16 h. After treatment, cell lysates were analyzed for HIF-1a
and AMPK protein levels and AMPK phosphorylation at Thr172. Lower panels: summary data (*p,0.05 vs. control;
#p,0.05 vs. OA-NO2 group; n=3).
C) BAECs were incubated with OA-NO2 (2.5 mM) for the indicated times. Intracellular Ca
2+ was measured with Fluo-4 fluorescent dye as described in
Materials and Methods. *p,0.01 vs. control (n=4). D) BAECs were pre-treated with YC-1 (30 mM) or BAPT-AM (25 mM) for 30 min or HIF-1a siRNA or
control siRNA for 48 h followed by incubation with OA-NO2 for 16 h. After treatment, intracellular Ca
2+ was measured in intact cells using a Fluo-4 NW
kit. *p,0.05 vs. control;
#p,0.05 vs. OA-NO2 group (n=3). E) BAECs were pre-loaded with 25 mM BAPT-AM for 30 min prior to incubation with
2.5 mM OA-NO2 for 16 h. AMPK protein levels and phosphorylation at Thr172 were detected as described above. Representative blots (top) and
densitometric analyses (bottom) are shown. Values are means 6 SD from three independent measurements. *p,0.05 vs. control;
#p,0.05 vs. OA-
NO2 group.
doi:10.1371/journal.pone.0031056.g005
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31056Figure 6. CaMKK is the upstream AMPKK that mediates OA-NO2-induced AMPK activation. A) HUVECs were treated with STO-609 (1 mM)
or KN-93 (3 mM) for 1 h followed by incubation with OA-NO2 for 16 h. AMPK and eNOS phosphorylation and protein expression were assayed as
described in Materials and Methods. The blot is representative of three blots obtained from three independent experiments. Lower panels: summary
data (*p,0.05 vs. control;
#p,0.05 vs. OA-NO2 group; n=3). B) HUVECs were incubated with CaMKKb-specific siRNA or control siRNA for 48 h and
then treated with OA-NO2 for 16 h. After treatment, cell lysates were analyzed for AMPK and eNOS phosphorylation and protein levels. Lower panels:
summary data (*p,0.05 vs. control;
#p,0.05 vs. OA-NO2 group; n=3). C) HUVECs were pre-treated with YC-1 (30 mM) for 30 min followed by
incubation with OA-NO2 for 16 h. An immunoblot of AMPK precipitated with an anti-CaMKK antibody is shown. The blot is representative of three
blots obtained from three independent experiments. Lower panels: summary data (*p,0.05 vs. control;
#p,0.05 vs. OA-NO2 group; n=3).
doi:10.1371/journal.pone.0031056.g006
Figure 7. AMPK mediates OA-NO2-induced eNOS phosphorylation and NO production in BAECs. BAECs were treated with (A) different
concentrations of OA-NO2 for 16 h or (B)2 . 5mmol/L OA-NO2 for the indicated times. Lysates were analyzed by western blot for the indicated proteins.
The blot is representative of three blots obtained from three separate experiments. C) Western blot of phosphorylated AMPK and eNOS in OA-NO2-
stimulatedBAECs infected with Ad-DN-AMPK (MOI=50). Non-infected cellsor cellsinfected with Ad-GFPservedas controls. For A–C, thecorresponding
densitometric analyses are shown. *p,0.05 vs. control;
#p,0.05 vs. GFP with OA-NO2-treated group. D) NO release by OA-NO2-stimulated BAECs
infected with Ad-DN-AMPK (MOI=50) or Ad-GFP (control). *p,0.05 vs. non-transfected, no OA-NO2 group;
#p,0.05 vs. OA-NO2-treated, Ad-GFP group.
E) AMPK activitycorresponding toC andD above.*p,0.05vs.noOA-NO2 treatment,Ad-GFPgroup;
#p,0.05 vs.OA-NO2-treated,Ad-GFP group. F) The
proposed signaling pathway involved in AMPK/eNOS activation in response to OA-NO2 treatment in endothelial cells.
doi:10.1371/journal.pone.0031056.g007
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pression of HO-1 induces proliferation and formation of
capillary-like structures [39]. Thus, therapeutic induction of
HO-1 may be beneficial in the treatment of chronic inflamma-
tory diseases as well as cardiovascular diseases. Our results
indicate that OA-NO2 potently induced HO-1 protein expression
in endothelial cells. In agreement with our studies, other studies
have suggested that HO-1 expression is induced in human aortic
endothelial cells (HAECs) by LNO2, which shows a higher
potency in this context than other established stimuli, including
oxidized fatty acids and hemin. This induction of HO-1
expression by NO2-FA is not mediated by NO, NF-kB, or
PPARc [40]. A recent study conducted by Liu et al. [41]
suggested that AMPK activation regulates HO-1 gene expression
in endothelial cells via the Nrf2/antioxidant responsive element
signaling pathway and that HO-1 contributes to the biological
actions of this kinase. Our data do not exclude the possibility that
AMPK activation upregulates HO-1 expression at the gene
transcription level. As shown in Figure 1E, Ad-DN-AMPK
partially blocks OA-NO2-induced HO-1 protein levels, suggest-
ing that AMPK activation may play a small role in HO-1 protein
expression; however, OA-NO2 induces HO-1 expression 2.5-fold
as early as 4 h after incubation when AMPK is not yet activated
(Figure 1B), implying that OA-NO2 induces HO-1 directly or via
another unknown pathway. Thus, AMPK does not act upstream
of HO-1 production in this system. Current data supports the
idea that upregulation of human HO-1 expression by NO2-FA
requires synergy between the cAMP-dependent response element
and the AP-1 sequences in the 24.5 kb HO-1 promoter region
[6,40]; however, the mechanisms involved in these events remain
poorly characterized, and the identities of the signaling molecules
downstream of HO-1 that mediate the vascular protective effects
of nitrated lipids are not entirely known.
The novel finding of this study is that OA-NO2 induces HIF-
1a expression via HO-1 under non-hypoxic conditions. HIF-1,
which exists as a heterodimer composed of the HIF-1a and HIF-
1b subunits, has been shown to mediate numerous physiological
and pathophysiological responses to hypoxia. Under normoxic
conditions, however, HIF-1a is ubiquitinated and rapidly
degraded [42] and is thus present at very low levels under
these conditions. Under hypoxic conditions, the HIF-1a subunit
is induced. Because HIF-1b is constitutively expressed, HIF-1a
is responsible for conferring hypoxia sensitivity to heterodimeric
HIF-1. Using specific chemical inhibitors, we demonstrated that
ERK1/2 partially mediated HO-1–induced HIF-1a expression
(Figure 4). In addition to inducing HIF-1a expression, ERK1/2
has been reported to phosphorylate HIF-1a and to thereby
increase its activity [20]. The possibility that CO, a metabolite
of HO-1 [43], also plays a role in HIF-1a induction by HO-1
cannot be excluded by our data. A recent study by Chin et al.
[44] suggested that exposure of macrophages to CO resulted in
rapid HIF-1a activation and stabilization, which regulates the
expression of genes involved in inflammation, metabolism, and
cell survival. This previous study also provided evidence that
CO may serve as a signaling intermediary between HO-1 and
HIF-1a.
Another important find of the present study is that HIF-1a
contributes to an increase in [Ca
2+]i, which is responsible for
CaMKKb-dependent AMPK activation (Figure 5 and 6).
Pharmaceutical and genetic inhibitors of HIF-1a suppressed
OA-NO2-induced increases in [Ca
2+]i, suggesting that HIF-1a is
involved in the OA-NO2-induced mobilization of Ca
2+ in
endothelial cells. Previous studies demonstrated that hypoxia
evokes an increase in [Ca
2+]i in endothelial cells [45], and
presumably, the induction of HIF-1a contributes to this increase
in [Ca
2+]i under hypoxic conditions or under normoxic
conditions in the presence of induction factors that activate
HIF-1a. The mechanisms that are involved in endothelial Ca
2+
homeostasis within the vasculature following HIF-1a activation
are also largely unknown. Although HIF-1a has been reported to
regulate Ca
2+ homeostasis in pulmonary arterial smooth muscle
cells via upregulation of store-operated Ca
2+ channels and
enhanced Ca
2+ influx [24], the detailed mechanisms remain to
be elucidated.
Our results also showed that OA-NO2-stimulated AMPK
activation was inhibited by chelation of intracellular free Ca
2+,
selective inhibition of CaMKK by STO-609, selective inhibition of
Ca
2+/calmodulin-dependent protein kinase by KN-93, and
siRNA-mediated silencing of CaMKK-b expression (Figure 6).
In addition, the association between AMPK and CaMKK was
enhanced by OA-NO2 treatment. Taken together, these data
indicate that the HIF-1a/Ca
2+/CaMKK- pathway is crucial for
OA-NO2-induced AMPK activation. Furthermore, CaMKK-
mediated AMPK activation in endothelium has also recently been
reported in response to thrombin [46], adenosine diphosphate
(ADP) [47], and bradykinin [48].
Results from previous studies indicated that endothelial
AMPK may play an important physiological role in the function
of both endothelial cells and the cardiovascular system as a
whole; thus, activation of AMPK may provide an explanation for
the beneficial effects of OA-NO2 on these systems (see review
[49]). Our findings show that induction of the CaMKKb/
AMPK pathway by OA-NO2 in endothelial cells may have both
physiological and therapeutic relevance. First, endothelial
AMPK activation by OA-NO2 activates nitric oxide synthase
(via phosphorylation on Ser 1177) and elevates NO bioavail-
ability, and these effects may not only protect against early
events in atherogenesis, such as white cell adherence [50], but
may also prevent later steps in atherogenesis, including fibrous
plaque formation. Endothelial NO likely represents the most
important anti-atherogenic defense molecule in the vasculature
[50]. Nitrated lipids act as NO donors in vitro and are widely
considered to be a possible endogenous source of NO [51].
Enhanced NO production under hyperlipidemic and hypercho-
lesterolemic conditions, such as those that occur with obesity or
insulin-resistant status, however, has been associated with low
NO bioactivity [52]. Therefore, it is reasonable to postulate that
the presence of these nitrated products and the related AMPK/
eNOS/NO pathway in vivo m a ya c t u a l l yp l a yac o m p e n s a t o r y
role, providing an adjustable supply of NO to compensate for the
impaired NO bioactivity and endothelial-dependent vasorelax-
ation that is characteristic of the early steps of vascular disease.
Second, AMPK signaling acts as a novel regulator of angiogen-
esis and is specifically required for endothelial cell migration and
differentiation under conditions of hypoxia [53] or in response to
adiponectin [54]. Additionally, AMPK-dependent eNOS activity
is required for adequate endothelial tube formation [54]. As
described above, increased levels of nitrated lipids are formed in
the context of the hyperlipidemia associated with obesity and
insulin resistance. Thus, the induction of AMPK and angiogen-
esis by nitrated lipids may also represent an adaptive defense
mechanism against impaired angiogenesis and/or vascular injury
caused by obesity-related dislipidemia. The role that activated
AMPK plays in increasing fatty acid oxidation via phosphory-
lation and inhibition of ACC and leading to a decrease in the
concentration of malonyl-CoA is most important [55]. In
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glycerolipids in some tissues, either secondary to its effect on
fatty acid oxidation or via phosphorylation and inhibition of sn-
glycerophosphate acyltransferase, the first committed enzyme in
diacylglycerol and triglyceride synthesis [56]. Furthermore,
endothelial AMPK activity may inhibit glycerol-3-phosphate
acyltransferase, which is required for de novo synthesis of
diacylglycerol [56]. Thus, AMPK may lessen endothelial
diacylglycerol production (and thus protein kinase C activation)
both by reducing the availability of the FFA substrates required
for this synthesis and by directly inhibiting the enzyme that
catalyzes it.
In conclusion, we have demonstrated for the first time that
NO2-UFAs activate AMPK in endothelial cells by a mechanism
that depends on an increase in HO-1 followed by HIF-1a protein
expression and Ca
2+/CaMKKb activation. Our results also
indicate that AMPK activity is required for eNOS/NO produc-
tion in endothelial cells (Figure 7F). The present study further
suggests that AMPK activation by nitrated lipids may play an
essential role in compensating or protecting vascular endothelial
function against vascular injury in obesity-related dyslipidemia.
AMPK might be a valid therapeutic target for treating vascular
disorders in obesity and type II diabetes.
Materials and Methods
Materials
BAECs and cell culture media were obtained from Clonetics
Inc. (Walkersville, MD). HUVECs and cell culture media were
purchased from Cascade Biologics (Portland, OR). FFA-free
bovine serum albumin (BSA) and oleic acid were obtained from
Sigma (St. Louis, MO). ZnBG was purchased from Porphyrin
Products, Inc. (Logan, UT). OA-NO2 was obtained from Cayman
Chemical (Ann Arbor, MI), and AICAR was purchased from
Toronto Research Chemicals (Toronto, Canada). The MEK
inhibitors PD 98059 and UO 126 were obtained from Calbiochem
(La Jolla, CA). 3-(59-hydroxymethyl-29-furyl)-1-benzylindazole
(YC-1) was purchased from AG Scientific Inc. (San Diego, CA).
Antibodies against phospho-ACC (Ser79), phospho-AMPK
(Thr172), AMPK, phospho-LKB1 (Ser428), LKB1, and phos-
pho-eNOS (Ser1177) were purchased from Cell Signaling
(Beverly, MA). The antibodies against ACC were obtained from
Alpha Diagnostic International (San Antonio, TX). All other
chemicals and organic solvents were of the highest grade and were
obtained from Sigma.
Cell culture and adenoviral infection
BAECs were grown in EBM supplemented with 2% fetal
bovine serum and growth factors. HUVECs were maintained in
Medium 200 supplemented with a low-serum growth supplement
before use. All culture media were supplemented with both
penicillin (100 U/ml) and streptomycin (100 mg/ml). Cells
between passages 5 and 10 were used for all experiments. All
cells were incubated in a humidified atmosphere of 5% CO2/
95% air at 37uC. BAECs were infected with adenovirus encoding
a dominant-negative mutant form of AMPKa (Ad-DN-AMPK)
or green fluorescence protein (Ad-GFP) as a control. Infections
were performed in 80% confluent cultures of BAECs in media
containing 0.1% fetal bovine serum and recombinant adenovirus
at the indicated multiplicity of infection (MOI). Cultures were
incubated with adenoviruses for 48 h before experimentation.
Using these conditions, infection efficiency was typically at least
80%, as determined by GFP expression.
SiRNA-mediated gene silencing in endothelial cells
HUVECs or BAECs were transfected with LKB1 siRNA, HO-1
siRNA, HIF–1a siRNA, CaMKKb, or the corresponding
scrambled siRNA (negative control) for 48 h using Lipofectami-
ne
TM 2000 (Invitrogen) according to the manufacturer’s instruc-
tions. Infected cells were starved in serum-free medium for 6 h,
then exposed to the indicated concentrations of OA-NO2 or
vehicle for 24 h.
Measurement of NO production
For NO detection, BAECs grown in 24-well plates were
incubated for 30 min in the presence of 15 mM 4,5-diaminofluor-
escein diacetate (DAF-2 DA) in PBS or in PBS alone (control) in
the dark at 37uC. Cells were then washed with PBS to remove
excess DAF-2 DA, and the change in fluorescence over 15 min
was measured with excitation and emission wavelengths of 485
and 530 nM, respectively, at room temperature using a microplate
reader (FL 600, Bio-Tek). Changes in fluorescence were also
visualized with a fluorescence microscope (Olympus IX71), and
images were captured for analysis [57].
Measurement of intracellular Ca
2+
[Ca
2+]i was measured using a Fluo-4 NW kit from Invitrogen
according to the manufacturer’s instructions. In brief, BAECs were
treated with OA-NO2, control or HIF-1a siRNA, YC-1, or
BAPTA-AM. The culture medium was then aspirated, cells were
washed once with Hepes buffer (pH 7.4), and 1 ml of Hepes buffer
with fluorescent dye was added to the cells. After the cells were
incubated for 30 min, the fluorescence intensity was measured
with excitation and emission wavelengths of 485 and 520 nM,
respectively.
Western blot analysis
BAECs, HUVECs, or Hela-S3 cells were lysed in cold RIPA
buffer. Protein concentrations were determined using a bicinch-
oninic acid protein assay system (Pierce, Rockford, IL). Proteins
were analyzed by western blotting with ECL-Plus detection as
described previously [58]. Relative PPARc protein expression
was measured in HUVEC nuclear extracts as previously detailed
[59].
AMPK activity assay
AMPK activity was assayed in the presence and absence of
AMP (200 mM) using the SAMS peptide, as previously described
[60]. AMPK activity was calculated by determining the difference
in activity between both conditions.
Statistical analysis
Statistical comparisons of vasodilation were performed using a
two-way analysis of variance (ANOVA), and intergroup differ-
ences were analyzed using Bonferroni’s post-hoc test. Time-course
studies were analyzed using a repeated-measure ANOVA. All
other results were analyzed using a one-way ANOVA. Values are
expressed as mean 6 SD. P-values less than 0.05 were considered
significant.
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